QQ客服 官方微博 反馈留言

	Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats
	Xingxing Chen; Wenhua Ge; Tiancheng Dong; Jie Hu; Lingzhi Chen; Xiaofang Fan; Yongsheng Gong; Hao Zhou
刊名	Life Sciences
	2019
关键词	Spironolactone Endothelial-mesenchymal transition Fibrosis Adenosine A2A receptor Cardiorenal syndrome
ISSN号	0024-3205
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4602345
专题	湖南大学
作者单位	1.c Department of Clinical laboratory, Wenzhou Central Hospital, Wenzhou 325000, China a Department of Cardiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China 2.Department of Hypoxia Medical Research Laboratory, Wenzhou Medical University, Wenzhou 325000, China 3.Stomatological Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an 710004, China
推荐引用方式 GB/T 7714	Xingxing Chen,Wenhua Ge,Tiancheng Dong,et al. Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats[J]. Life Sciences,2019.
APA	Xingxing Chen.,Wenhua Ge.,Tiancheng Dong.,Jie Hu.,Lingzhi Chen.,...&Hao Zhou.(2019).Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats.Life Sciences.
MLA	Xingxing Chen,et al."Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats".Life Sciences (2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。